GPCRs as potential therapeutic targets in preeclampsia
Preeclampsia is an important obstetric complication that arises in 5% of women after the 20(th) week of gestation, for which there is no specific therapy and no cure. Although much of the recent investigation in this field has focused on soluble forms of the angiogenic membrane receptor tyrosine kinase Flt1 and the transforming growth factor β co-receptor Endoglin, there is significant clinical potential for several GPCR targets and their agonists or antagonists in preeclampsia. In this review,...[Show more]
|Collections||ANU Research Publications|
|Source:||Drug discovery today. Disease models|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.